Sobi enters Research Collaboration with Affibody within the IL-1 field
Sobi has signed a research collaboration and option agreement with the Swedishbiotech company Affibody AB for the discovery and development of noveltreatments for inflammatory diseases where Interleukin-1 (IL-1) is implicated.The research will be based on Affibody's proprietary technology platformsAffibody® molecules and Albumod(TM) and includes up to five different targetswithin the IL-1 field. All targets are key proteins involved in the regulationof human immune and inflammatory processes. One project is a lead candidate forthe inhibition of IL-1 beta at the preclinical phase, and